14/09/2026 AbelZeta’s C-CAR168 received FDA IND clearance for PMS Takeda’s zasocitinib won US FDA priority review in PsO. AbelZeta’s C-CAR168 received FDA IND clearance for PMS. (Ref) The US FDA cleared AbelZeta Pharma’s Investigational New Drug (IND) application for a Phase 1b/2 trial of C-CAR168 (an anti-CD20/BCMA bispecific CAR-T), in patients with progressive multiple sclerosis (PMS) refractory to standard therapy. The clearance expanded C-CAR168’s development into refrac